Erratum: Alzheimer disease β-amyloid activity mimics cholesterol oxidase (Journal of Clinical Investigation (2000) 115 (2556-2563) DOI:10.1172/JCI23610);Alzheimer disease β-amyloid activity mimics cholesterol oxidase

Journal of Clinical Investigation

Volumn 115, Issue 9, 2005, Pages 2556-2563

  Puglielli, Luigi ^a,f   Friedlich, Avi L ^a   Setchell, Kenneth D R ^b   Nagano, Seiichi ^a,g   Opazo, Carlos ^c   Cherny, Robert A ^c   Barnham, Kevin J ^c   Wade, John D ^c   Melov, Simon ^d   Kovacs, Dora M ^a   Bush, Ashley I ^a,c,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLEST 4 EN 3 ONE; CHOLESTEROL; CHOLESTEROL OXIDASE; CLIOQUINOL; COPPER ION; HYDROGEN PEROXIDE; OXYGEN; STAUROSPORINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; AUTOPSY; BRAIN; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NERVE CELL CULTURE; NEUROLOGIC DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 24644475272     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI23610C1     Document Type: Erratum

References (65)

1. Bhadra, S., et al. 1991. Oxidation of cholesterol moiety of low density lipoprotein in the presence of human endothelial cells or Cu+2 ions: identification of major products and their effects. Biochem. Biophys. Res. Commun. 176:431-440.
2. Liu, K.Z., Cuddy, T.E., and Pierce, G.N. 1992. Oxidative status of lipoproteins in coronary disease patients. Am. Heart J. 123:285-290.
3. Chang, Y.H., Ahdalla, D.S., and Sevanian, A. 1997. Characterization of cholesterol oxidation products formed by oxidative modification of low density lipoprotein. Free Radic. Biol. Med. 23:202-214.
4. Brown, A.J., et al. 2000. Cholesterol and oxysterol metabolism and subcellular distribution in macrophage foam cells. Accumulation of oxidized esters in lysosomes. J. Lipid Res. 41:226-237.
5. Launer, L.J., White, L.R., Perrovitch, H., Ross, G.W., and Curb, J.D. 2001. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 57:1447-1452.
6. Pappolla, M.A., et al. 2002. Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis [review]. Free. Radic. Biol. Med. 33:173-181.
7. Smith, C.D., et al. 1991. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 88:10540-10543.
8. Nunomura, A., et al. 2001. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:759-767.
9. Smith, M.A., et al. 1998. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70:2212-2215.
10. Atwood, C.S., et al. 1998. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273:12817-12826.
11. Atwood, C.S., et al. 2000. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an artomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75:1219-1233.
12. Curtain, C., et al. 2001. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276:20466-20473.
13. Curtain, C.C., et al. 2003. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 278:2977-2982.
14. Huang, X., et al. 1999. Cu(II) potentiation of Alzheimer Abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274:37111-37116.
15. 2. J. Biol. Chem. 277:40302-40308.
16. Zhang, Q., et al. 2004. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101:4752-4757.
17. Dietschy, J.M., and Turley, S.D. 2001. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12:105-112.
18. Mori, T., et al. 2001. Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice. J. Neuropathol. Exp. Neurol. 60:778-785.
19. Refolo, L.M., et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7:321-331.
20. Li, L., Cao, D., Garber, D.W., Kim, H., and Fukuchi, K. 2003. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 163:2155-2164.
21. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., and Markesbery, W.R. 1998. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158:47-52.
22. Dong, J., et al. 2003. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry. 42:2768-2773.
23. Navas, J., Gonzalez-Zorn, B., Ladron, N., Garrido, P., and Vazquez-Boland, J.A. 2001. Identification and mutagenesis by allelic exchange of choE, encoding a cholesterol oxidase from the intracellular pathogen Rhodococcus equi. J. Bacteriol. 183:4796-4805.
24. Lario, P.I., Sampson, N., and Vrielink, A. 2003. Sub-atomic resolution crystal structure of cholesterol oxidase: what atomic resolution crystallography reveals about enzyme mechanism and the role of the FAD cofactor in redox activity. J. Mol. Biol. 326:1635-1650.
25. DeGrella, R.F., and Simoni, R.D. 1982. Intracellular transport of cholesterol to the plasma membrane. J. Biol. Chem. 257:14256-14262.
26. Gutteridge, J.M., and Wilkins, S. 1983. Copper salt-dependent hydroxyl radical formation. Damage to proteins acting as antioxidants. Biochim. Biophys. Acta. 759:38-41.
27. Cherny, R.A., et al. 2001. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:665-676.
28. Ritchie, C.W., et al. 2003. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer's disease: a pilot phase 2 clinical trial. Arch. Neurol. 60:1685-1691.
29. Shapiro, R., and Djerassi, C. 1964. Mass spectrometry in structural and stereochemical problems. L. Fragmentation and hydrogen migration reactions of a,b-unsaturated 3-keto steroids. J. Am. Chem. Soc. 86:2825-2832.
30. Djerassi, C., Karliner, J., and Aplin, R. 1965. Mass spectrometry in structural and stereochemical problems. LXXVIII. Steroidal D4-3,6-diketones. Steroids. 6:1-8.
31. Smith, A., and Brooks, C. 1975. Mass spectra of D4-and 5a-3-ketosteroids formed during the oxidation of some 3b-hydroxysteroids by cholesterol oxidase. Biomed. Mass Spectrom. 3:81-87.
32. Thenot, J.-P., and Horning, E. 1972. MO-TMS derivatives of human urinary steroids for GC and GC-MS studies. Anal. Lett. 5:21-33.
33. Axelson, M., and Sjovall, J. 1978. Separation and configuration of syn and anti isomers of testosterone oxime. Anal. Lett. B11:229-237.
34. Setchell, K.D., Alme, B., Axelson, M., and Sjovall, J. 1976. The multicomponent analysis of conjugates of neutral steroids in urine by lipophilic ion exchange chromatography and computerised gas chromatography-mass spectrometry. J. Steroid Biochem. 7:615-629.
35. Liu, K.Z., Maddaford, T.G., Ramjiawan, B., Kutryk, M.J., and Pierce, G.N. 1991. Effects of cholesterol oxidase on cultured vascular smooth muscle cells. Mol. Cell. Biochem. 108:39-48.
36. Kellner-Weibel, G., Geng, Y.J., and Rothblat, G.H. 1999. Cytotoxic cholesterol is generated by the hydrolysis of cytoplasmic cholesteryl ester and transported to the plasma membrane. Atherosclerosis. 146:309-319.
37. Abramov, A.Y., Canevari, L., and Duchen, M.R. 2003. Changes in intracellular calcium and glutachione in astrocytes as the primary mechanism of amyloid neurotoxicity. J. Neurosci. 23:5088-5095.
38. Barnham, K.J., et al. 2004. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 18:1427-1429.
39. Tickler, A.K., et al. 2005. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J. Biol. Chem. 280:13355-13363.
40. Lee, J.Y., Friedman, J.E., Angel, I., Kozak, A., and Koh, J.Y. 2004. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging. 25:1315-1321.
41. Ciccotosto, G.D., et al. 2004. Enhanced toxicity and cellular binding of a modified amyloid peptide with a methionine to valine substitution. J. Biol. Chem. 279:42528-42534.
42. Nelson, T.J., and Alkon, D.L. 2005. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 280:7377-7387.
43. Sayre, L.M., et al. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:2092-2097.
44. Pratico, D., et al. 2000. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48:809-812.
45. Mark, R.J., Lovell, M.A., Markesbery, W.R., Uchida, K., and Mattson, M.P. 1997. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 68:255-264.
46. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., and Lee, V.M. 2001. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21:4183-4187.
47. Bjorkhem, I., and Karlmar, K.E. 1974. Biosynthesis of cholestanol: conversion of cholesterol into 4-cholesten-3-one by rat liver microsomes. Biochim. Biophys. Acta. 337:129-131.
48. Cali, J.J., Hsieh, C.L., Francke, U., and Russell, D.W. 1991. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266:7779-7783.
49. MacLachlan, J., Wotherspoon, A., Ansell, R., and Brooks, C. 2000. Cholesterol oxidase: sources, physical properties and analytical applications [review]. J. Steroid Biochem. Mol. Biol. 72:169-195.
50. Wood, W.G., Igbavboa, U., Rao, A.M., Schroeder, F., and Avdulov, N.A. 1995. Cholesterol oxidation reduces Ca(2+) + MG (2+)-ATPase activity, interdigitation, and increases fluidity of brain synaptic plasma membranes. Brain Res. 683:36-42.
51. Menkes, J.H., Schimschock, J.R., and Swanson, P.D. 1968. Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch. Neurol. 19:47-53.
52. Salen, G., Shefer, S., and Tint, G.S. 1984. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis. Gastroenterology. 87:276-283.
53. Ghoshroy, K.B., Zhu, W., and Sampson, N.S. 1997. Investigation of membrane disruption in the reaction catalyzed by cholesterol oxidase. Biochemistry. 36:6133-6140.
54. Huang, X., et al. 1999. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry. 38:7609-7616.
55. Maynard, C.J., et al. 2002. Overexpression of Alzheimer's disease β-amyloid opposes the age-dependent elevations of brain copper and iron levels. J. Biol. Chem. 277:44670-44676.
56. Bayer, T.A., et al. 2003. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 100:14187-14192.
57. Phinney, A.L., et al. 2003. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl. Acad. Sci. U. S. A. 100:14193-14198.
58. White, A.R., et al. 1999. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842:439-444.
59. Bellingham, S.A., et al. 2004. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J. Neurochem. 91:423-428.
60. Barnham, K.J., et al. 2003. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278:42959-42965.
61. Ehehalt, R., Keller, P., Haass, C, Thiele, C., and Simons, K. 2003. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160:113-123.
62. Puglielli, L., et al. 2001. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3:905-912.
63. Hutter-Paier, B., et al. 2004. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron. 44:227-238.
64. Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98:5815-5820.
65. Callahan, M.J., et al. 2001. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158:1173-1177.